Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Keiko Komuro"'
Autor:
Shunsuke Kondo, Yuki Katsuya, Kan Yonemori, Keiko Komuro, Masatoshi Sugeno, Toshio Kawata, Dana Ghiorghiu, Didier Meulendijks, Noboru Yamamoto
Publikováno v:
Cancer Treatment and Research Communications, Vol 39, Iss , Pp 100809- (2024)
Introduction: We aimed to assess the safety, pharmacokinetic profile, and antitumor activity of adavosertib monotherapy in Japanese patients with advanced solid tumors. Materials and methods: This was a single-center, open-label, phase I study with t
Externí odkaz:
https://doaj.org/article/c5e3b71ea3544fcba7e6ccf11b726a69
Autor:
Daisuke, Shinoda, Hiroyuki, Tsukagoshi, Keiko, Komuro, Daisuke, Yoshida, Toshikazu, Yanaoka, Mariko, Saito, Nobuhiro, Saruki
Publikováno v:
Japanese Journal of Infectious Diseases. 75:530-532
Respiratory infections are common, and the most common causative agent is a virus. Therefore, routine surveillance of respiratory viruses is useful in the case of novel viral diseases such as coronavirus disease 2019 (COVID-19). In this study, to cla
Autor:
Yutaka Fujiwara, Yasuo Takahashi, Morihito Okada, Takumi Kishimoto, Shunsuke Kondo, Koshi Fujikawa, Manabu Hayama, Masatoshi Sugeno, Shinya Ueda, Keiko Komuro, Mark Lanasa, Takashi Nakano
Publikováno v:
Oncologist
Background The primary objective of this phase I, open-label trial was to assess safety and tolerability of tremelimumab monotherapy and combination therapy with durvalumab in Japanese patients with advanced cancer. Tremelimumab is a fully human mono
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39231c03ef97ce344d67716280206415
https://europepmc.org/articles/PMC9438922/
https://europepmc.org/articles/PMC9438922/
Autor:
Masahiro Nii, Toshiyuki Kozuki, Manabu Hayama, Haruo Iguchi, Noboru Yamamoto, Shinya Ueda, Gordana Vlahovic, Yutaka Fujiwara, Mariko Sugimoto, Keiko Komuro
Publikováno v:
Cancer Science
Blockade of programmed cell death ligand-1 with durvalumab has shown efficacy and safety in large, international studies of patients with advanced solid tumors. A phase 1, non-randomized, open-label multicenter study was initiated to evaluate durvalu